LATEST
Gaza’s Winter Emergency Exposes the Failure to Enforce the CeasefireAustralian Journalist Accuses Media Giants of Shielding Israel and Silencing Palestinian Voices186,000 Arabic Posts Flagged, Five in Hebrew: The Fight Over Gaza’s Public RecordAs Gaza’s Tents Flood and Claim Young Lives, Israel's Channel 14 Turns Palestinian Suffering into a Water Park JokeSecret UK Arms Files Reveal Wartime Exports and Unanswered Questions Over Israel RestrictionsTO THE NEW Joins SpaceX Super Intelligence Partner Network to Scale AI-Assisted DevelopmentNobel Peace Prize Laureate Urges Israelis to Act Over Gaza Genocide as American Jewish Dissent DeepensTerry Dubrow: “You Can’t Trust Every Company Selling GLP-1 Drugs Online.” So He Founded One.Pia and Joshua Filler Introduce KillerFillers Jump, Break, and Jump/Break Tip Line Developed with TitlistA2C and Andrea Pusateri Bring “Here for the Ride” to Sardinia for a Five-Stage Grand Loop Cycling ChallengeGaza’s Winter Emergency Exposes the Failure to Enforce the CeasefireAustralian Journalist Accuses Media Giants of Shielding Israel and Silencing Palestinian Voices186,000 Arabic Posts Flagged, Five in Hebrew: The Fight Over Gaza’s Public RecordAs Gaza’s Tents Flood and Claim Young Lives, Israel's Channel 14 Turns Palestinian Suffering into a Water Park JokeSecret UK Arms Files Reveal Wartime Exports and Unanswered Questions Over Israel RestrictionsTO THE NEW Joins SpaceX Super Intelligence Partner Network to Scale AI-Assisted DevelopmentNobel Peace Prize Laureate Urges Israelis to Act Over Gaza Genocide as American Jewish Dissent DeepensTerry Dubrow: “You Can’t Trust Every Company Selling GLP-1 Drugs Online.” So He Founded One.Pia and Joshua Filler Introduce KillerFillers Jump, Break, and Jump/Break Tip Line Developed with TitlistA2C and Andrea Pusateri Bring “Here for the Ride” to Sardinia for a Five-Stage Grand Loop Cycling Challenge
Business

ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310

Richard Powell  2 min read

ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for PMN310 for the treatment of AD.

  “This submission is an important milestone for the ProMIS team as we advance our lead compound, PMN310, toward the clinic. We are excited to continue the development of PMN310 to potentially provide a new treatment option with a differentiated profile for patients with Alzheimer’s disease,” said Gail Farfel, Ph.D., Chief Executive Officer of ProMIS Neurosciences. “We look forward to our transition to a clinical stage company, pending regulatory clearance of the IND.”  

PMN310 is a novel monoclonal antibody which is designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) that are believed to be a major driver of AD, as opposed to monomers or plaque. In preclinical studies, PMN310 showed strong ex vivo target engagement of toxic oligomers in brain samples from patients with AD. In a recent presentation of in vitro data at the AD/PD 2023 conference, PMN310 compared to other Aβ-directed antibodies was the least impacted by monomer competition, resulting in an overall greater toxic oligomer binding level versus all comparators. In addition, PMN310’s lack of off-target binding to Aβ plaque also suggests the possibility of a more favorable safety profile, since off-target plaque binding by Aβ-directed antibodies has been associated with Aβ-related imaging abnormalities (ARIA). These data support a potentially differentiated clinical profile when compared to other antibody therapeutics in AD, either approved or currently in development.

 

ProMIS Neurosciences Inc. is a development stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts. ProMIS is listed on Nasdaq and the Toronto Stock Exchange under the symbol PMN.

 

http://www.promisneurosciences.com

Related articles

Top